LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blocking ITK Activity Slows Growth of Malignant Melanoma in Mouse Model

By LabMedica International staff writers
Posted on 13 May 2015
Print article
Image: Molecular model of IL2 inducible T-cell kinase (ITK) enzyme (Photo courtesy of Wikimedia Commons).
Image: Molecular model of IL2 inducible T-cell kinase (ITK) enzyme (Photo courtesy of Wikimedia Commons).
Development of malignant melanoma was found to depend to some extent on the activity of the enzyme produced by the gene interleukin-2 (IL2) inducible T-cell kinase (ITK).

Investigators at the University of North Carolina (Chapel Hill, USA) used an ITK-specific monoclonal antibody to probe sections from formalin-fixed paraffin-embedded tumor blocks or melanoma cell line arrays. ITK was visualized by immunohistochemistry (IHC).

Results published in the May 1, 2015, issue of the journal Clinical Cancer Research revealed that ITK was expressed at greater levels in primary and metastatic melanomas than in non-cancerous moles. In metastatic melanoma samples, 91% had higher expression levels than of the non-cancerous moles.

Treatment of melanoma-bearing mice with a low molecular weight ITK inhibitor reduced growth of ITK-expressing xenografts or established native melanomas.

“We have discovered that ITK is highly expressed in melanoma even though it was thought to be restricted to immune cells, and when you inhibit it, you decrease melanoma growth,” said senior author Dr. Nancy E. Thomas, professor of dermatology at the University of North Carolina. “Therefore, we think it is a good potential drug target.”

Related Links:
University of North Carolina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more